JPRN-UMIN000004596已完成未知
Evaluation of dorzolamide/timolol fixed combination therapy for the patients who need more IOP reduction under PG analogues - Evaluation of dorzolamide/timolol fixed combination therapy
Department of Ophthalmology, Kyoto Prefectural University of Medicine0 个研究点目标入组 40 人开始时间: 2010年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) patients who received any surgical therapy within the past 3 months (incl. laser surgery) 2) difficult to measure IOP with GAT 3) difficult to check the fundus due to the corneal opacity or cataract 4) any patients who are expected to receive any surgical procedures during the study periods 5) contraindication of beta blockers or dorzolamide 6) any allergic history to the timilol or dorzolamide 7) women who are under pregnant or lactation period 8) any one who is considered to be inappropriate for this study
研究者
相似试验
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analoguesprimary open angle glaucoma and ocular hypertensionJPRN-UMIN000006828Hospital, University of the Ryukyus40
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues and CAIGlaucomaJPRN-UMIN000006830Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues and beta-blockerGlaucomaJPRN-UMIN000006829Hospital, University of the Ryukyus20
已完成
不适用
Evaluation of dorzolamide/timolol fixed-dose combination therapy for the patients who need more IOP (trough & peak) reduction under treatment of PG analogues, beta-blocker and CAIJPRN-UMIN000006831Hospital, University of the Ryukyus20
已完成
不适用
Multicentre comparative clinical trial of the safety and efficacy of a 0.5% timolol-2% dorzolamide-0.2% brimonidine ophthalmic solution in fixed combination (formulated by Laboratorios Sophia S.A. de C.V.) versus Cosopt® in open angle glaucoma or ocular hypertensioISRCTN26988657aboratorios Sophia S.A de C.V. (Mexico)100